SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. Founded in 2000, SomaLogic is a global leader in proteomics. Powered by an industry-leading technology platform and one of the largest clinical proteomic database in the world, we aim to revolutionize precision medicine to help address unmet medical needs. We understand the importance of real-time data and actionable information when it comes to health, which is why we provide patients with knowledge on their current health status through analyzing their personal protein data. SomaLogic’s pioneering platform provides more coverage of the proteome than any other technology. SomaLogic currently measures approximately 7,000 proteins, more than twice as many as other proteomic technology platforms. The proprietary SomaScan® Assay measures proteins with high specificity, low variance and high reproducibility, which enables the possibility of faster, more precise drug discovery. SomaLogic’s A.I. and machine learning-powered bioinformatics algorithms, operated in tandem with the company’s database of more than 450,000 protein samples, helped to create a growing suite of SomaSignal™ tests. These tests are clinical proteomic diagnostics that provide additional insights into the current health status of patients and the future risk of conditions and diseases with a small blood sample.